– Generated positive data from the Phase 1 clinical trial of ENTR-601-44 for DMD, including dose-dependent...
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage...
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse...
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.